Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor
- 6 April 2007
- journal article
- Published by Elsevier in Cellular Signalling
- Vol. 19 (8) , 1754-1764
- https://doi.org/10.1016/j.cellsig.2007.03.011
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Sphingosine and Its Analog, the Immunosuppressant 2-Amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, Interact with the CB1 Cannabinoid ReceptorMolecular Pharmacology, 2006
- Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinusesNature Immunology, 2005
- The Heart Rate Decrease Caused by Acute FTY720 Administration Is Mediated by the G Protein-Gated Potassium Channel IKAChAmerican Journal of Transplantation, 2005
- Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart RateJournal of Biological Chemistry, 2004
- Discovery of new G protein-coupled receptors for lipid mediatorsJournal of Lipid Research, 2004
- The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptorsThe FASEB Journal, 2004
- Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I studyTransplantation, 2003
- Prevention of autoimmune diabetes by FTY720 in nonobese diabetic miceTransplantation, 2002
- Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase‐3βThe FASEB Journal, 2002
- Increased concentrations of phosphatidate, diacylglycerol and ceramide in ras- and tyrosine kinase (fps)-transformed fibroblastsOncogene, 1997